ロード中...
The role of dasatinib in the management of chronic myeloid leukemia
Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) for chronic, blastic, or accelerated phase chronic myeloid leukemia (CML) patients who are resistant or intolerant to previous treatment. It potently inhibits BCR/ABL and SRC-family kinases (SRC, LCK, HCK, YES, FYN, FGR, BLK, LYN, FRK)...
保存先:
| 出版年: | Drug Des Devel Ther |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4330036/ https://ncbi.nlm.nih.gov/pubmed/25709401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S80207 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|